title: Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats.
abstract: The effect of a unilateral 6-hydroxydopamine (6-OHDA) lesion of the left medial forebrain bundle and 3 weeks treatment with L-DOPA of normal and 6-OHDA lesioned rats on CB1r mRNA expression was investigated by in situ hybridization. A 6-OHDA lesion of nigrostriatal pathway alone, confirmed by the loss of nigral tyrosine hydroxylase mRNA, did not alter CB1r mRNA levels in the dopamine depleted striatum. Similarly, chronic L-DOPA treatment of normal rats had no effect on striatal CB1r mRNA expression. In contrast, chronic L-DOPA treatment of 6-OHDA-lesioned rats significantly increased CB1r mRNA expression in the denervated striatum. These results suggest that the CB1r activity may be altered by L-DOPA's action and this may be related to the treatment of Parkinson's disease.
authors.affiliation: Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London, UK.
authors.forename: B Y
authors.initials: BY
authors.lastname: Zeng
authors.forename: B
authors.initials: B
authors.lastname: Dass
authors.forename: A
authors.initials: A
authors.lastname: Owen
authors.forename: S
authors.initials: S
authors.lastname: Rose
authors.forename: C
authors.initials: C
authors.lastname: Cannizzaro
authors.forename: B C
authors.initials: BC
authors.lastname: Tel
authors.forename: P
authors.initials: P
authors.lastname: Jenner
mesh_terms: D018663:Adrenergic Agents; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D015259:Dopamine Agents / Q000494:pharmacology*; D007980:Levodopa / Q000494:pharmacology*; D008297:Male; D008474:Medial Forebrain Bundle / Q000293:injuries; D016627:Oxidopamine; D010300:Parkinson Disease / Q000378:metabolism; D012333:RNA, Messenger / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000187:drug effects* / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000187:drug effects / Q000378:metabolism
chemical_list: D018663:Adrenergic Agents; D015259:Dopamine Agents; D012333:RNA, Messenger; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D007980:Levodopa; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase